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Article

Renal Function and Proteinuria after Successful
Immunosuppressive Therapies in Patients with FSGS
Ronald J. Hogg, Aaron Friedman, Tom Greene, Milena Radeva, Milos N. Budisavljevic, Jennifer Gassman,
Debbie S. Gipson, J. Ashley Jefferson, Eunice G. John, Frederick J. Kaskel, Asha Moudgil, Marva Moxey-Mims, Luis A. Ortiz,
Jeffrey R. Schelling, William Schnaper, Tarak Srivastava, Howard Trachtman, V. Matti Vehaskari, Craig Wong,
Robert P. Woronieki, Scott K. Van Why, and Anna Zolotnitskaya

Summary
Background and objectives In the FSGS Clinical Trial, 22 cyclosporine-treated and 20 mycophenolate/
dexamethasone-treated patients experienced a complete or partial remission after 26 weeks, completed 52 weeks
of treatment, and were studied through 78 weeks. Herein, changes in the urine protein/creatinine ratio (UP/C)
and estimated GFR (eGFR) throughout the entire study period are deﬁned.
Design, setting, participants, and measurements The FSGS Clinical Trial, which was conducted from November
2004 to January 2010, enrolled patients aged 2–40 years, with eGFR $40 ml/min per 1.73 m2 and UP/C .1
mg/mg after $4 weeks of corticosteroid therapy. Both groups received lisinopril or losartan throughout the
study. UP/C and eGFR were measured at 0, 26, 52, and 78 weeks.
Results The median UP/C in the cyclosporine- and mycophenolate/dexamethasone-responsive patients fell by
89.8% and 82.7% at 52 weeks; the fall was largely sustained at 78 weeks (74.7% and 80.3%, respectively). The
mean eGFR fell by 19.4% in the cyclosporine group and rose by 7.0% in the mycophenolate mofetil/
dexamethasone group at 52 weeks, but subsequently rose by 16.4% and fell by 2.6%, respectively, in the two
groups from 52 to 78 weeks.
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Conclusions In this subset of responding FSGS patients, the improvement in UP/C after cyclosporine or
mycophenolate/dexamethasone treatment was largely sustained for 6 months after therapy. Reduction in eGFR
in the cyclosporine group was improved 6 months after cyclosporine was stopped although the levels were lower
than baseline in seven patients who entered the study with decreased eGFR.
Clin J Am Soc Nephrol 8: 211–218, 2013. doi: 10.2215/CJN.08330812

Introduction
Many reports have suggested that decreasing the level
of proteinuria in patients with FSGS reduces the longterm effect of this disease on GFR (1–3), but it is unclear whether all methods of reducing proteinuria will
have the same potential. Other concerns include the
apparent lack of persistent effect on proteinuria when
therapies such as cyclosporin A (CsA) are discontinued (4–8), and the potential for nephrotoxicity when
CsA is continued over many years. This has led to
considerable variability in the duration of treatment,
ranging from 6 months to $2 years.
The National Institutes of Health (NIH)–sponsored
clinical trial of CsA versus mycophenolate mofetil
(MMF) and dexamethasone (DEX) in patients with
FSGS was recently published (9). Our results showed
that 39 patients (54.2%) in the CsA group and 26 patients (39.4%) in the MMF/DEX group achieved a
complete or partial remission after 6 months of therapy and went on to complete a 12-month course. In
the primary outcome analysis of this trial, we noted a
greater reduction in proteinuria after 26 weeks of
www.cjasn.org Vol 8 February, 2013

treatment with CsA compared with MMF/DEX (26
week/baseline UP/C median ratios of 0.24 versus
0.46, respectively; P=0.04). However, there was
also a greater reduction in the 26-week/baseline
GFR ratio in the CsA group (0.73) compared with
the MMF/DEX group (0.95) over the same period of
follow-up (P=0.001). Although the GFR rose during
the 26-week period after CsA treatment was discontinued, this improvement did not return the GFR to
the original level in this group (9). This report further
delineates the time course and relationship between
changes in UP/C and estimated GFR (eGFR) during
and 6 months after 12 months of treatment with CsA
or MMF/DEX in patients who showed a complete or
partial remission at 26 weeks.

Materials and Methods
The FSGS Clinical Trial was a 78-week multi-center,
prospective, open label, randomized controlled trial
(RCT) that compared CsA in the control arm versus
DEX in combination with MMF (MMF/DEX) as the
Copyright © 2013 by the American Society of Nephrology
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experimental therapy. Patients were eligible to enter this
trial if they had primary FSGS conﬁrmed by central pathologists, were aged between 2 and 40 years, had an eGFR
$40 ml/min per 1.73 m2, and had a UP/C .1 g/g after a
minimum of 4 weeks of corticosteroid therapy. Details of
the inclusion and exclusion criteria were provided in a
prior publication (10).
Monitoring of Laboratory Studies
All laboratory assays were conducted in a central laboratory. Two ﬁrst-morning urine samples were obtained at
baseline and after the patients had been treated for 26, 52,
and 78 weeks and the results were expressed as the mean
of the two measurements. If the two UP/C values differed
by .50%, a third urine sample was collected and the two
results closest to one another were used to determine the
mean UP/C. GFR was estimated by the Schwartz formula
in patients aged ,18 years (11) and by the Cockroft–Gault
formula (adjusted for body surface area) in patients aged
$18 years (12).
Treatment Regimens
All patients were given 0.3 mg/kg of prednisone or
prednisolone (maximum 15 mg) every other day for the
ﬁrst 6 months of the trial. An angiotensin converting
enzyme (ACE) inhibitor, lisinopril, was given to all patients who tolerated this drug for the entire 18 months of
the trial. Dosages of lisinopril were initiated at approximately 0.1 mg/kg per day (25% of the target dose) and
increased every 2 weeks as tolerated until the target dose of
0.4 mg/kg (40 mg maximum daily) was reached. Losartan
(maximum dosage 100 mg/d) was provided to ACE
inhibitor–intolerant patients. Management of edema and
control of BP were left to the discretion of the participating
investigators.
In the CsA arm, an initial dosage of 5–6 mg/kg per day
(maximum 250 mg/d) was given in two equal doses. The
subsequent doses were adjusted to achieve 12-hour trough
level concentrations of 100–250 ng/ml, or in response to
prespeciﬁed toxicities (reductions were applied in 30%
decrements).
In the MMF/DEX arm, an initial dosage of MMF (25–36
mg/kg per day, maximum 2 g/d), was given in two equal
daily doses, and DEX (0.9 mg/kg per dose, maximum 40
mg) was given on two consecutive days at the start of
weeks 1–8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 30, 34, 38, 42,
46, and 50. MMF and DEX dose adjustments were made in
30% decrements for prespeciﬁed toxicities. Treatment with
CsA or MMF/DEX was given for up to 52 weeks, depending on response, whereas lisinopril or losartan was given
for 78 weeks.
Treatment Failure
Treatment failure in this trial was deﬁned as failure to
achieve at least a partial remission by week 26, failure to
achieve a partial or complete remission by week 52, or if a
patient reached a protocol-deﬁned stop point. Complete
remission was deﬁned as UP/C ,0.2; partial remission was deﬁned as UP/C ,2.0 plus 50% decrease compared with baseline. Study stop points included a 50%
decline from baseline in the eGFR, onset of dialysis, or

prespeciﬁed severe medication related toxicity. After the conﬁrmation of treatment failure, all study medications were
discontinued. Thus, only patients who had at least a partial
remission at week 26 received 12 months of treatment with
CsA or MMF/DEX.
Entry Criteria for Inclusion in This Post Hoc Analysis
The cohort of patients that forms the basis of this post hoc
analysis of the FSGS Clinical Trial consists of patients with
complete data who experienced a partial remission or
complete remission at 26 weeks in the study, completed
52 weeks of CsA or MMF/DEX treatment, were seen and
had laboratory studies done at the 78-week visit (after the
primary study drugs had been withdrawn for 26 weeks),
and did not receive any immunosuppressive agents between weeks 52 and 78 of the study. All of the patients
continued to receive lisinopril or losartan from 52 to 78
weeks at the same doses they received during the ﬁrst 52
weeks of the study.
Ethical Considerations
This study was registered with ClinicalTrials.gov (identiﬁer NCT00135811) and was monitored by a data and
safety monitoring board that was established by the NIH.
The study protocol was reviewed and approved by the
institutional review board at each participating site.
Statistical Analyses
In this report, we consider changes in eGFR and UP/C
over the follow-up period conditional on achievement of
remission of proteinuria at week 26 and other conditions
related to the maintenance of the patient’s randomly assigned treatment regimen and data completeness. Because
inclusion of patients in the analysis is dependent on their
outcome, patients who were retained for analyses may not
be strictly comparable between the treatment groups.
Therefore, statistical analyses are limited to assessments
of change within each of the two treatment groups, and
we present no formal statistical comparisons of the treatment groups to each other.
Baseline characteristics of the patients are summarized as
frequencies and percentages for categorical variables, and
as medians with 10th–90th percentile ranges for most of
the numeric variables. The eGFR data are shown as
mean 6 1 SD. For each of the two treatment groups, baseline summaries are provided for all randomized patients
and separately for those meeting the criteria for inclusion
in the analyses and for those not meeting the inclusion
criteria. Fisher exact tests, t tests, or Wilcoxon rank-sum
tests were used as appropriate to compare these two subgroups within each of the two randomized treatment
groups.
Levels of eGFR and UP/C were summarized at the
baseline and follow-up week 26, 52, and 78 visits and
expressed as mean 6 1 SD for eGFR and median plus
10th–90th percentile ranges for UP/C. Changes from baseline to 26, 52, and 78 weeks, and from week 52 to week 78
were summarized as mean 6 1 SD for eGFR and as median percentage changes plus 10th–90th percentiles for
UP/C. The statistical signiﬁcance of the changes in eGFR
and in UP/C was evaluated separately for each treatment
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group. The data analysis for this paper was generated using SAS/STAT software, version 9.3 of the SAS System for
UNIX.

Results
Patient Baseline Characteristics
Tables 1 and 2 show the baseline characteristics of the 42
patients who fulﬁlled the basis for this subanalysis, the 96
patients who did not fulﬁll the entry criteria and the entire
cohort of patients (N=138). The numbers of patients fulﬁlling all of the above-listed criteria were 22 in the CsA
group (Table 1) and 20 in the MMF/DEX group (Table 2).
This group of patients completed 12 months of CsA or
MMF/DEX, was maintained on ACE inhibitors/angiotensin receptor blockers throughout the 18-month trial, and
had no missing data. They tended to have lower baseline
levels of UP/C and serum cholesterol, and higher serum
albumin levels than the patients who were not included in
this subanalysis. This resulted in part from the fact that, by
deﬁnition, they all had at least a partial remission, which
required a fall in UP/C to ,2.0 in addition to a 50% reduction. Patients were more likely to achieve a partial remission, as deﬁned here, and be eligible to complete the
12 months of study drugs if their UP/C was lower at
baseline. Although 39 patients in the CsA group and 26
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patients in the MMF/DEX group had a partial or complete remission at 26 weeks, 17 and 6 patients, respectively, in the two groups did not fulﬁll all of the criteria
and are not included in this analysis. The reasons for their
exclusion are listed in Table 3. Note that failure to
maintain a complete or partial remission at the 52-week
visit did not constitute a reason for exclusion from this
analysis.
The left side of Table 4 shows the mean eGFR and median UP/C values at weeks 0, 26, 52, and 78 in the 22 CsA
responsive patients who fulﬁlled entry criteria for this post
hoc study. The right side of Table 4 shows percentage
changes in the mean eGFR and median UP/C ratios in
these patients at weeks 26, 52, and 78 compared with baseline. The eGFR values fell signiﬁcantly in the CsA group at
weeks 26 and 52 compared with baseline, but the levels
returned toward baseline in most of the patients by the
week 78 visit. As shown in the table, most of the decrease
in both eGFR and UP/C in the CsA group occurred in the
ﬁrst 6 months of therapy. When analyzed separately, the
mean eGFR and median UP/C levels in the CsA group at
week 26 were not signiﬁcantly different from those at
week 52. Table 5 shows comparable data in the 20
MMF/DEX responsive patients. The eGFR levels in the
MMF/DEX group of patients remained stable throughout
the study. As with the CsA group, most of the decrease in

Table 1. Baseline characteristics of patients randomized to CsA

Baseline Factor
Age at Enrollment (yr)
White race
Male sex
Baseline GFR (ml/min
per 1.73m2)
UP/C (mg/mg)
Serum Albumin (g/d)
Serum Cholesterol (mg/dl)
Hypertensive

All Randomized
(n 5 72)

Patients in This
Substudy (A) (n 5 22)

Patients not in This
Substudy (B) (n 5 50)

P Value (A)
versus (B)

15 (4–34)
40 (55.6)
40 (55.6)
136.6 6 79.0

15 (7–34)
15 (68.2)
13 (59.1)
126.8 6 50.5

15 (2.5–32)
25 (50.0)
27 (54.0)
140.9 6 88.8

0.52
0.47
0.80
0.49

4.4 (1.2–13.3)
3.0 (1.7–4.1)
283 (203–571)
41 (56.9)

2.7 (1.1–5.1)
3.5 (2.6–4.2)
259 (163–354)
13 (59.1)

5.4 (1.3–15.4)
2.6 (1.6–4.0)
318 (233–597)
28 (56.0)

0.002
0.003
0.01
1.00

Data shown as median (10th–90th percentile), n (%), or mean 6 SD. CsA, cyclosporin A; UP/C, urinary protein/creatinine ratio.

Table 2. Baseline characteristics of patients randomized to MMF/DEX

Baseline Factor
Age at Enrollment (yr)
White race
Male sex
Baseline GFR (ml/min
per 1.73m2)
UP/C (mg/mg)
Serum albumin (g/d)
Serum cholesterol (mg/dl)
Hypertensive

All Randomized
(n 5 66)
14.5 (6–35)
38 (57.6)
33 (50)
132.0 6 73.6
3.7 (1.2–13.1)
2.7 (1.6–4.0)
312 (221–569)
39 (59.1)

Patients not in This
Substudy (D) (n 5 46)

P Value (C)
versus (D)

14 (9.5–34.5)
13 (65.0)
12 (60.0)
122.6 6 50.7

15 (5–35)
25 (54.3)
21 (45.6)
136.2 6 81.7

0.68
0.71
0.42
0.49

3.6 (1.1–9.6)
3.2 (1.9–4.0)
271.5 (187–480)
13 (65.0)

4.0 (1.5–13.6)
2.6 (1.5–4.0)
365 (232–589)
26 (56.5)

0.17
0.10
0.02
0.59

Patients in This
Substudy (C) (n 5 20)

Data shown as median (10th–90th percentile), n (%), or mean 6 SD.
MMF/DEX, mycophenolate mofetil/dexamethasone; UP/C, urinary protein/creatinine ratio.
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UP/C levels in the MMF/DEX group occurred in the ﬁrst
6 months and the decrease from 26 weeks to 52 weeks was
not statistically signiﬁcant. Figures 1, 2, 3, and 4 show the
timeline of individual eGFR and UP/C values in the two
groups of patients.

Table 3. Reasons for exclusion from this analysis of patients
who achieved partial or complete remission at week 26

Missing eGFR, UP/C, or
medication information
at week 52 or week 78
Not on all prescribed
study medications
at week 52
Nonstudy immunosuppressive drug (e.g., CsA,
tacrolimus)
given between week 52
and week 78
Total

CsA
Group (n)

MMF/DEX
Group (n)

10

2

2

4

5

0

17

6

CsA, cyclosporin A; MMF/DEX, mycophenolate mofetil/
dexamethasone; eGFR, estimated GFR; UP/C, urinary protein/
creatinine ratio.

Subtyping of FSGS Lesions
The distribution of lesions in the CsA group was as
follows: collapsing (n=2), tip (n=2), peri-hilar (n=4), and
not otherwise speciﬁed (n=14). The lesions in the MMF/
DEX group were collapsing (n=2), tip (n=4), cellular (n=1),
and not otherwise speciﬁed (n=13). The number of patients
with each of these lesions was insufﬁcient for analysis to
predict whether the changes in eGFR or UP/C were related to the histology.

Discussion

The results of this post hoc analysis show that most of our
patients with FSGS who had a good response to a 12-month
course of CsA or MMF/DEX were able to maintain this response over the subsequent 6 months. These results are in
conﬂict with some previous statements regarding the risk of
increasing levels of proteinuria when CsA therapy is discontinued in patients with FSGS who show a complete or partial remission. For example, Burgess concluded that “relapse
after reducing or stopping CsA is very common” in these
patients (4). This was based on evidence that was available
in 1999 (4). Burgess rated the evidence for this statement as
grade B-level 2 (RCT with surrogate end point). However,
the trial used to provide this evidence, by Ponticelli et al. in
1993, included only 14 patients who were given CsA for 6
months, after which patients with complete or partial remission received a tapering dose over the next 6 months (5).

Table 4. eGFR and UP/C levels at weeks 0, 26, 52, and 78 in 22 patients responding to CsA

eGFR and UP/C Level
Week

0
26
52
78

% Change in eGFR and UP/C

eGFR
mean 6 SD
(ml/min
per 1.73 m2)

UP/C median
(10th–90th
percentiles)
(mg/mg)

Change
(wk)

126.8650.5
109.1657.1
103.3649.3
118.4653.2

2.7 (1.1–5.1)
0.3 (0.1–1.0)
0.2 (0.1–1.1)
0.6 (0.1–1.6)

0–26
0–52
0–78
52–78

eGFR
mean 6SD (%)

P Value

UP/C median
(10th–90th
percentiles) (%)

P Value

217.0613.3
219.4613.9
28.4613.3
+16.4624.3

,0.001
,0.001
0.01
0.004

289.4 (296.2 to 262.4)
289.8 (296.9 to 268.7)
274.7 (296.4 to 235.6)
+40.3 (227.3 to +581.8)

,0.001
,0.001
,0.001
0.001

CsA, cyclosporin A; eGFR, estimated GFR; UP/C, urinary protein/creatinine.

Table 5. eGFR and UP/C levels at weeks 0, 26, 52, and 78 in 20 patients responding to MMF/DEX

eGFR and UP/C Level
Week

0
26
52
78

% Change in eGFR and UP/C

eGFR
mean 6 SD
(ml/min per
1.73 m2)

UP/C median
(10th–90th
percentiles)
(mg/mg)

Change
(wk)

122.6650.7
119.7646.3
128.9657.0
126.1658.9

3.6 (1.1–9.6)
0.8 (0.2–1.5)
0.5 (0.1–2.6)
0.8 (0.1–3.3)

0–26
0–52
0–78
52–78

eGFR
mean 6 SD (%)
+0.8623.1
+7.0625.7
+3.8628.5
22.6616.6

P Value

UP/C
median
(10th–90th
percentiles) (%)

P Value

0.88
0.24
0.56
0.50

276.2 (291.9 to 259.7)
282.7 (297.0 to 230.4)
280.3 (294.5 to 20.7)
+25.0 (250.2 to 268.3)

,0.001
,0.001
,0.001
0.06

MMF/DEX, mycophenolate mofetil/dexamethasone; eGFR, estimated GFR; UP/C, urinary protein/creatinine.
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Figure 1. | Line diagram of individual eGFR results and the mean eGFR from week 0 to week 78 in CsA-responsive patients. eGFR, estimated
GFR; CsA, cyclosporin A.

Figure 2. | Line diagram of individual UP/C ratios and the median UP/C from week 0 to week 78 in CsA-responsive patients. UP/C, urinary
protein/creatinine ratio; CsA, cyclosporin A.

Eight of the patients received the full 12 months of therapy:
ﬁve of these patients were in relapse at the end of 12 months
and two were in complete or partial remission.
Additional information was provided by Cattran et al.
for the North American Nephrotic Syndrome Study Group

(6). They conducted an RCT comparing 6 months of therapy with CsA in 26 FSGS patients versus placebo in 23
patients. The mean dosage of CsA over the treatment period was 4.2 mg/kg per day. ACE inhibitors were not
permitted during the treatment period but were allowed,
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Figure 3. | Line diagram of individual eGFR results and the mean eGFR from week 0 to week 78 in MMF/DEX-responsive patients. eGFR,
estimated GFR; MMF/DEX, mycophenolate mofetil/dexamethasone.

Figure 4. | Line diagram of individual UP/C ratios and the median UP/C from week 0 to week 78 in MMF/DEX-responsive patients. UP/C,
urinary protein/creatinine ratio; MMF/DEX, mycophenolate mofetil/dexamethasone.

albeit not required, in the follow-up period. Partial remission (n=15) or complete remission (n=3) occurred in 18
CsA-treated patients (69% of total). Eight of these 18 patients (44%) relapsed within 6 months of stopping CsA and
an additional three patients (17%) relapsed in the

subsequent 6 months. Cattran et al. proposed that future
trials should consider longer CsA treatment periods.
A high rate of relapse in CsA-responsive adult FSGS
patients was reported by Heering et al. in 2004 (7). CsA
treatment was given as initial therapy for varying periods

Clin J Am Soc Nephrol 8: 211–218, February, 2013
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of time in 34 patients. All patients received a minimum of
6 months of treatment with CsA and the total duration of
CsA therapy was 23616 months. Complete or partial remission was seen in 21 of 34 patients, for an overall response rate of 62%. A relapse occurred in 14 of 18 patients
in whom withdrawal was attempted (78%).
The only controlled trial of CsA in children with FSGS
was conducted by Lieberman et al., who reported the effect of high-dose CsA in 12 patients who completed 6
months of therapy (8). The target whole blood level of
CsA was 300–500 mg/ml by polyclonal RIA. All 12 patients in the CsA group showed reduction in their level of
proteinuria. Unfortunately, there is no information on the
rate of relapse in this group of children. It is interesting to
note, however, that their complete remission/partial remission response rate was superior to that seen in other
trials, perhaps due to the higher doses of CsA that were
used.
It is not clear why the increase in proteinuria after
immunosuppression in our patients was less than those
described previously. One possibility is that all patients in
our complete remission/partial remission group received
12 months of therapy with CsA, whereas other studies
required only 6 months of treatment, with optional tapering doses subsequently. A second possibility is that our
study may have selected “better responders” by requiring
patients to achieve a ﬁrst-morning UP/C level ,2.0 as
well as a 50% reduction, which is common to most studies,
to be deﬁned as partial remission, whereas other studies
only required the 24-hour urine protein excretion to be
,3.5 g/d (13). A third possibility is the beneﬁt of continued use of ACE inhibitors after CsA or MMF/DEX was
stopped. This is consistent with the recent report from
Kangovi et al. that described a better outcome in children
with FSGS who received ACE inhibitor or angiotensin receptor blocker therapy as ﬁrst-line treatment rather than
immunosuppressive drugs (14). The results in our study
and the Kangovi trial (14) raise questions as to the relative
beneﬁt versus risk of these different forms of therapy, especially in patients with relatively low UP/C ratios. We
are unable to answer this question on the basis of our
results.
Our study was also able to examine changes in eGFR.
There was a signiﬁcant fall in eGFR in the CsA patients
while the therapy was being administered, but this effect
was reversed signiﬁcantly when the treatment was discontinued (Table 3). This was despite ongoing therapy
with lisinopril or losartan. It must be acknowledged that
our analysis was conﬁned to patients who responded well
to CsA therapy and it is not possible to extrapolate the
results to all patients with FSGS who are treated with
CsA. It should also be noted that the eGFR did not return
to baseline in any of the seven patients who entered the
study with eGFR ,90 ml/min per 1.73 m2. The mean
eGFR fell from 74 at baseline to 60 ml/min per 1.73 m2
at the 78-week visit in these seven patients.
Although MMF has been reported to be of some beneﬁt
when given separately to patients with FSGS (15–18),
response to the combined use of this agent with DEX
and the subsequent clinical course of the patients after
therapy was stopped have not been described. Our
MMF/DEX-responsive patients had eGFR and proteinuria
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measurements that were relatively stable throughout the
course of therapy and beyond. In this subset of responding
FSGS patients, the decrease in UP/C in response to CsA or
MMF/DEX was largely sustained for 6 months after therapy. Reduction in eGFR in the CsA group was much improved 6 months after CsA was stopped.
The FSGS Clinical Trial study design included some
similar features to previous reports in the literature but
differed in a number of ways that should be noted. We
opted to provide the immunosuppressive medications for
12 months, but only if a patient showed a least a partial
remission after 6 months and all of our patients received
ACE inhibitors after the immunosuppression was discontinued. Previous studies of CsA that used a 6-month course
or 6 months plus a tapering dose for an additional 6 months
were more often associated with increased levels of proteinuria after therapy. We hypothesize that a longer course
might produce a more sustained response, especially when
the patients continue to receive an ACE inhibitor.
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